Advertisement

Topics

ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services

08:00 EST 10 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
ERS Genomics Ltd. and Cellecta, Inc. announced today a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property for use in informing research t...

Other Sources for this Article

ERS Genomics:
MacDougall Biomedical Communications
Mario Brkulj or Dr. Stephanie May
Direct: +49 89 2420 9345 or +48 89 2420 9344
mbrkulj@macbiocom.com or smay@macbiocom.com
or
Cellecta:
Cellecta, Inc.
Paul Diehl, 650-938-4050
pauld@cellecta.com
or
Media:
Ruth Mercado, 650-938-4080
rmercado@cellecta.com

NEXT ARTICLE

More From BioPortfolio on "ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...